Friday, December 5, 2008
Morning Symposia: 7:00 a.m. - 11:00 a.m
- Emerging Approaches in Apoptotic and Cell Cycle Control of Hematopoietic Malignancies
- Allogeneic Transplantation: Applying New Research for Improved Outcomes
Emerging Approaches in Apoptotic and Cell Cycle Control of Hematopoietic Malignancies
This program is sponsored by the University of Medicine and Dentistry of New Jersey Center for Continuing and Outreach Education and supported by the Leukemia and Lymphoma Society.
| Location: | Moscone Center West, Level 3, Room 3000/3002/3004 | |
| Speakers: | Jerry Adams, PhD, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
|
|
| Selina Chen-Kiang, PhD, Weill Cornell Medical College, New York, NY
|
||
| Stephen Fesik, PhD, Abbott Laboratories, Abbott Park, IL
|
||
| John Reed, MD, PhD, Burnham Institute, La Jolla, CA |
This symposium will present the latest scientific understanding of cell cycle control and apoptosis and the current efforts to develop drugs targeted at these pathways. This will be a true bench-to-bedside symposium useful for basic scientists and clinicians.
For more information, contact:
Allyson O’Connor, Leukemia and Lymphoma Society
Phone: 914-821-8838
Fax: 914-821-3638
Allogeneic Transplantation: Applying New Research for Improved Outcomes
This program is sponsored by the Medical College of Wisconsin and supported by the National Marrow Donor Program.
| Location: | Moscone Center South, Exhibit Level, Room 104 | |
| Speakers: | Dennis Confer, MD, National Marrow Donor Program, Minneapolis, MN
|
|
| Claudio Anasetti, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
|
||
| Mary Horowitz, MD, Medical College of Wisconsin, Milwaukee, WI
|
||
| Alois Gratwohl, MD, University Hospital Basel, Basel, Switzerland |
Clinical advances in allogeneic transplantation have led to expanded patient eligibility, improved outcomes, and dramatic growth. This session will focus on new research that defines when transplantation should be considered, whether outcomes are different between related and unrelated donors, the current state of HLA matching, and insight into the future. Clinicians will be provided with a translational approach to determining patient eligibility, the appropriate timing of transplantation, and ultimately improving survival outcomes.
For more information, contact:
Renee Ryan, National Marrow Donor Program
Phone: 612-884-8430
Fax: 612-627-5877